BT Poised to Sell TNT Sports Stake to Warner Bros. Discovery

Published 9 hours agoWBD

BT Poised to Sell TNT Sports Stake to Warner Bros. Discovery

BT is close to finalizing a deal to sell its 50% stake in UK sports broadcaster TNT Sports to Warner Bros. Discovery (WBD), as reported by the Financial Times. This potential transaction comes ahead of WBD's option to buy BT's share outright before the end of 2026, showcasing the companies' strategic maneuvering in the competitive media landscape.

BT values its stake in the joint venture at over £750 million according to its books, although the actual sale price is expected to be noticeably lower. The move is part of BT CEO Allison Kirkby's broader strategy to pivot the company’s focus towards its core mobile and broadband services, a direction that aligns with shifts across the media industry. TNT Sports, which was established in 2022 from the merger of BT Sport and Eurosport UK, manages broadcasting rights to premier sporting events including the Premier League and UEFA Champions League.

The potential sale is indicative of a larger trend where media companies are reassessing traditional cable TV holdings in favor of streaming and content production initiatives. Such strategic shifts are becoming increasingly necessary as consumers and markets lean more toward digital and streaming content. Both BT and WBD have chosen not to comment further on the ongoing negotiations.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Oppenheimer Retains 'Perform' Rating for Acadia Pharmaceuticals Amid Study Results

Oppenheimer Retains 'Perform' Rating for Acadia Pharmaceuticals Amid Study Results

11 minutes agoACAD

Oppenheimer has reaffirmed its 'Perform' rating for Acadia Pharmaceuticals, setting a price target of $19. This update follows the recent outcomes from the Phase 3 ADVANCE-2 study regarding pimavanserin, intended for the treatment of schizophrenia negative symptoms, which did not achieve its primary goal. As reported by Investing.com, Acadia Pharmaceuticals has decided to cease further development of pimavanserin for this indication. In response to these results, Acadia is realigning its focus on other strategic areas. This includes generating free cash flow from its existing medication, Nuplazid, successfully launching Daybue, and progressing ongoing trials targeting Alzheimer’s disease psychosis and Prader-Willi syndrome. The company's strategy also involves pursuing new business development opportunities. These efforts aim to strengthen its market presence and leverage existing products to maintain growth despite the recent setback with pimavanserin.

Analysts Show Optimism for Enliven Therapeutics with Increased Price Targets

Analysts Show Optimism for Enliven Therapeutics with Increased Price Targets

26 minutes agoENLV

Contrary to rumors of a price target cut by JonesResearch, recent analyst activities suggest a more positive outlook for Enliven Therapeutics with several firms updating their estimates. Baird notably raised its price target for the company from $32 to $40 on November 15, 2024, while maintaining an "Outperform" rating, according to nasdaq.com. This adjustment reflects a continued belief in the company's potential. Additionally, HC Wainwright joined this optimistic trend by increasing its price target for Enliven from $37 to $39 on March 21, 2025. The firm assigned a "Buy" rating, further underscoring the confidence within the financial community. These updates highlight the recent wave of analyst favorability toward Enliven's stock. As of April 17, 2024, the average one-year price target for Enliven was documented at $35.02, representing a 10.75% rise from earlier estimates. This positive reassessment by analysts points to a robust sentiment surrounding Enliven Therapeutics' anticipated financial performance and its strategic direction in the months ahead.

Jefferies Lowers Price Target for Flowers Foods Amid Retail Pressures

Jefferies Lowers Price Target for Flowers Foods Amid Retail Pressures

40 minutes agoFLO

Jefferies recently revised its price target for Flowers Foods (NYSE: FLO) from $20 to $16, while maintaining a 'Hold' rating. This change comes as the company faces increased retail volume pressures, particularly in the bread category during the holiday season, as highlighted by Jefferies analyst Rob Dickerson. Reuters reported that these challenges are more pronounced now compared to the third quarter. The analyst pointed out that despite Flowers Foods ramping up promotional efforts, along with its competitors, there are concerns regarding the necessity of deep promotions to achieve sustainable volume growth. This suggests a challenging landscape for maintaining sales without sacrificing profit margins. Despite these pressures, Flowers Foods boasts strong financial health with a current ratio of 1.24 and a solid record of increasing dividends for 11 consecutive years. Furthermore, its recent $795 million acquisition of Simple Mills is a strategic move to diversify and expand into the snacking market. The 'Hold' rating reflects a balanced view, acknowledging both the company's robust fundamentals and the hurdles posed by the competitive market environment.

Jefferies Lowers Adobe Price Target Amid AI Monetization Concerns

Jefferies Lowers Adobe Price Target Amid AI Monetization Concerns

55 minutes agoADBE

Jefferies has adjusted its outlook on Adobe, reducing the price target from $700 to $650 while maintaining a 'Buy' rating, as reported by Nasdaq. The key concern for the adjustment centers around Adobe's ability to effectively monetize its generative AI technologies. While the company's strategic outlook remains positive, investors are awaiting more concrete results. Additionally, Adobe's fiscal 2025 revenue guidance, projected to be between $23.3 billion and $23.55 billion or about 9% growth, is seen as conservative by Jefferies, according to Wall Street Jedi. Despite this cautious guidance, Jefferies notes that Adobe has a history of issuing conservative forecasts and later surpassing them. Jefferies' commentary reflects unease over Adobe's immediate growth potential against the backdrop of a broader technological transition. Historically, Adobe has often outperformed its initial conservative guidance, indicating a possible reassurance for investors familiar with its strategic execution.